Forty-three percent of melanoma patients have chronic complications from immunotherapies
Virus-based therapy may unlock potential of immunotherapy for glioblastoma
25 March 2021Variant sweeps Hungary to world-high weekly COVID death rate
25 March 2021Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
